HYPOGONADOTROPIC HYPOGONADISM 16 WITH OR WITHOUT ANOSMIA
|
0.600 |
GeneticVariation
|
disease |
UNIPROT |
The prevalence of CHD7 missense versus truncating mutations is higher in patients with Kallmann syndrome than in typical CHARGE patients.
|
25077900 |
2014 |
HYPOGONADOTROPIC HYPOGONADISM 16 WITH OR WITHOUT ANOSMIA
|
0.600 |
GeneticVariation
|
disease |
UNIPROT |
SEMA3A, a gene involved in axonal pathfinding, is mutated in patients with Kallmann syndrome.
|
22927827 |
2012 |
HYPOGONADOTROPIC HYPOGONADISM 16 WITH OR WITHOUT ANOSMIA
|
0.600 |
Biomarker
|
disease |
GENOMICS_ENGLAND |
SEMA3A, a gene involved in axonal pathfinding, is mutated in patients with Kallmann syndrome.
|
22927827 |
2012 |
HYPOGONADOTROPIC HYPOGONADISM 16 WITH OR WITHOUT ANOSMIA
|
0.600 |
GeneticVariation
|
disease |
UNIPROT |
SEMA3A deletion in a family with Kallmann syndrome validates the role of semaphorin 3A in human puberty and olfactory system development.
|
22416012 |
2012 |
HYPOGONADOTROPIC HYPOGONADISM 16 WITH OR WITHOUT ANOSMIA
|
0.600 |
Biomarker
|
disease |
CTD_human |
|
|
|
Kallmann Syndrome
|
0.360 |
GeneticVariation
|
disease |
BEFREE |
By analyzing protein expression and processing, we did not observe any differences of the p.I668V variant compared with wild-type SEMA3A, while a pathogenic SEMA3A variant p.R66W recently described in a patient with Kallmann syndrome did affect protein secretion.
|
29432577 |
2018 |
Kallmann Syndrome
|
0.360 |
Biomarker
|
disease |
BEFREE |
SEMA3A and SEMA7A were screened by Sanger sequencing in altogether 50 Finnish HH patients (34 with Kallmann syndrome (KS; HH with hyposmia/anosmia) and 16 with normosmic HH (nHH)).
|
24522099 |
2014 |
Kallmann Syndrome
|
0.360 |
AlteredExpression
|
disease |
BEFREE |
By performing knockdown experiments for Chd7 in Xenopus laevis embryos, we found abnormalities in the expression pattern of Sema3a, a protein involved in the pathogenesis of Kallmann syndrome, in vivo.
|
24728844 |
2014 |
Kallmann Syndrome
|
0.360 |
GeneticVariation
|
disease |
BEFREE |
SEMA3A, a gene involved in axonal pathfinding, is mutated in patients with Kallmann syndrome.
|
22927827 |
2012 |
Kallmann Syndrome
|
0.360 |
Biomarker
|
disease |
BEFREE |
SEMA3A is therefore a new gene whose loss-of-function is involved in KS.
|
22416012 |
2012 |
Kallmann Syndrome
|
0.360 |
GermlineCausalMutation
|
disease |
ORPHANET |
SEMA3A is therefore a new gene whose loss-of-function is involved in KS.
|
22416012 |
2012 |
Kallmann Syndrome
|
0.360 |
Biomarker
|
disease |
BEFREE |
Strikingly, mice lacking SEMA3A or semaphorin signalling through both NRP1 and NRP2 recapitulate the anatomical features of a single case of KS analysed so far, and may therefore be used as genetic models to elucidate the pathogenesis of KS.
|
21059704 |
2011 |
Malignant neoplasm of breast
|
0.320 |
AlteredExpression
|
disease |
BEFREE |
Stilbenoid-Mediated Epigenetic Activation of Semaphorin 3A in Breast Cancer Cells Involves Changes in Dynamic Interactions of DNA with DNMT3A and NF1C Transcription Factor.
|
31327173 |
2019 |
Malignant neoplasm of breast
|
0.320 |
AlteredExpression
|
disease |
BEFREE |
Among 1,980 breast cancer cases from a public database, the ratio of VEGF and SEMA3A in primary tumors (n = 450) of hormone-receptor-negative breast cancer is associated with ARHGAP17 expression inversely, and with disease free survival.
|
29971782 |
2018 |
Schizophrenia
|
0.320 |
Biomarker
|
disease |
PSYGENET |
In a sample of 245 nuclear families (n=1074) originating from the same geographical region as the families revealing the linkage, SNP and microsatellite association analyses of the four regional candidate genes, GRM3, RELN, SEMA3A and VGF, revealed no significant association to the clinical diagnosis of schizophrenia.
|
17684500 |
2008 |
Schizophrenia
|
0.320 |
Biomarker
|
disease |
PSYGENET |
The PLXNA2 ligand semaphorin 3A has been shown to be upregulated in the cerebellum of individuals with schizophrenia.
|
16402134 |
2006 |
Schizophrenia
|
0.320 |
AlteredExpression
|
disease |
BEFREE |
The PLXNA2 ligand semaphorin 3A has been shown to be upregulated in the cerebellum of individuals with schizophrenia.
|
16402134 |
2006 |
Schizophrenia
|
0.320 |
AlteredExpression
|
disease |
LHGDN |
The results show that sema3A is elevated in schizophrenia, and is associated with downregulation of genes involved in synaptic formation and maintenance.
|
12610647 |
2003 |
Schizophrenia
|
0.320 |
Biomarker
|
disease |
PSYGENET |
The results show that sema3A is elevated in schizophrenia, and is associated with downregulation of genes involved in synaptic formation and maintenance.
|
12610647 |
2003 |
Schizophrenia
|
0.320 |
Biomarker
|
disease |
BEFREE |
The results show that sema3A is elevated in schizophrenia, and is associated with downregulation of genes involved in synaptic formation and maintenance.
|
12610647 |
2003 |
Malignant neoplasm of breast
|
0.320 |
GeneticVariation
|
disease |
UNIPROT |
|
|
|
Hypogonadotropic hypogonadism
|
0.110 |
AlteredExpression
|
disease |
BEFREE |
Chd7 regulates the expression of Sema3a, which also contributes to the pathogenesis of Kallmann syndrome, a heterogeneous condition with the typical features hypogonadotropic hypogonadism and an impaired sense of smell.
|
29432577 |
2018 |
Alcoholic Intoxication, Chronic
|
0.110 |
Biomarker
|
disease |
BEFREE |
SEMA3A variation is significantly and replicably associated with comorbid AD and MD in African American participants.
|
29071344 |
2017 |
Alcoholic Intoxication, Chronic
|
0.110 |
GeneticVariation
|
disease |
GWASCAT |
Genetic Risk Variants Associated With Comorbid Alcohol Dependence and Major Depression.
|
29071344 |
2017 |
Major Depressive Disorder
|
0.110 |
GeneticVariation
|
disease |
BEFREE |
SEMA3A variation is significantly and replicably associated with comorbid AD and MD in African American participants.
|
29071344 |
2017 |